Viewing Study NCT00003041



Ignite Creation Date: 2024-05-05 @ 11:07 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00003041
Status: COMPLETED
Last Update Posted: 2013-01-31
First Post: 1999-11-01

Brief Title: Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Organization: National Cancer Institute NCI

Study Overview

Official Title: Phase II Evaluation of Pyrazoloacridine NSC 366140 in Patients With Metastatic Breast Cancer
Status: COMPLETED
Status Verified Date: 2002-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of pyrazoloacridine in treating women who have refractory metastatic breast cancer
Detailed Description: OBJECTIVES I Determine the efficacy of pyrazoloacridine in patients with refractory breast cancer II Determine the toxic effects of pyrazoloacridine in these patients

OUTLINE Patients receive pyrazoloacridine IV over 3 hours Treatment repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity

PROJECTED ACCRUAL A total of 12-35 patients will be accrued for this study within 1 year

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-T96-0120 None None None
OSU-9712 None None None